University of California, Los Angeles (UCLA)
Santa Monica, California 90404
4 studies enrolling now · 14 studies all time
What they study most
Advanced Solid Tumor, Breast Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Diffuse Large B-cell Lymphoma, Endometrial Adenocarcinoma, Endometrial Neoplasms, Epithelial Tumor, Esophageal Neoplasms, Fallopian Tube Cancer, HER2-positive Bladder Cancer, HER2-positive Breast Cancer
Studies at this site
- A Study of LY4257496 in Participants With Cancer (OMNIRAY) — Recruiting now
- MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
- A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma — Recruiting now
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients — Recruiting now
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors — Running, not enrolling
- Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) — Running, not enrolling
- Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) — Stopped early
- A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer — Running, not enrolling
- Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma — Completed
- PRS-343 in HER2-Positive Solid Tumors — Completed
- Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) — Completed
- Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) — Stopped early
- First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) — Completed
- Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects — Completed